If approved, and I think it will, the thrice-weekly Copaxone will be strongly promoted by Teva but I think they might have too little time to convert before it goes generic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.